ITeos Therapeutics Inc (ITOS) 20 Days SMA touch 11.89%: Odds are Looking very much in favour

ITeos Therapeutics Inc (NASDAQ: ITOS) started the day on Wednesday, with a price increase of 3.47% at $13.12, before settling in for the price of $12.68 at the close. Taking a more long-term approach, ITOS posted a 52-week range of $8.20-$18.24.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -23.53%. Meanwhile, its Annual Earning per share during the time was -40.62%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -46.75%. This publicly-traded company’s shares outstanding now amounts to $35.84 million, simultaneously with a float of $28.53 million. The organization now has a market capitalization sitting at $470.22 million. At the time of writing, stock’s 50-day Moving Average stood at $10.99, while the 200-day Moving Average is $11.35.

ITeos Therapeutics Inc (ITOS) Ownership Facts and Figures

Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. ITeos Therapeutics Inc’s current insider ownership accounts for 20.40%, in contrast to 81.31% institutional ownership. According to the most recent insider trade that took place on Oct 12 ’23, this organization’s Chief Financial Officer bought 5,000 shares at the rate of 8.37, making the entire transaction reach 41,850 in total value, affecting insider ownership by 19,429. Preceding that transaction, on Aug 23 ’23, Company’s sold 350,000 for 16.26, making the whole transaction’s value amount to 5,692,673. This particular insider is now the holder of 1,804,058 in total.

ITeos Therapeutics Inc (ITOS) Earnings and Revenue Records

In the latest quarterly report released, which was put into the public domain on 12/30/2023, the organization reported -$0.85 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$1.03) by $0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.24 per share during the current fiscal year.

ITeos Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -46.75% and is forecasted to reach -5.99 in the upcoming year.

ITeos Therapeutics Inc (NASDAQ: ITOS) Trading Performance Indicators

Let’s observe the current performance indicators for ITeos Therapeutics Inc (ITOS). It’s Quick Ratio in the last reported quarter now stands at 13.76. The Stock has managed to achieve an average true range (ATR) of 0.65. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 37.32.

In the same vein, ITOS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.15, a figure that is expected to reach -0.98 in the next quarter, and analysts are predicting that it will be -5.99 at the market close of one year from today.

Technical Analysis of ITeos Therapeutics Inc (ITOS)

If we take a close look at the recent performances of ITeos Therapeutics Inc (NASDAQ: ITOS), its last 5-days Average volume was 0.56 million that shows progress from its year to date volume of 0.29 million. During the previous 9 days, stock’s Stochastic %D was recorded 75.93% While, its Average True Range was 0.68.

Raw Stochastic average of ITeos Therapeutics Inc (ITOS) in the period of the previous 100 days is set at 85.98%, which indicates a major rise in contrast to 81.11% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 68.17% that was higher than 58.05% volatility it exhibited in the past 100-days period.